The genetic changes that lead to acute myeloid leukemia (AML) can begin more than 50 years before diagnosis, according to research published in Nature, offering new opportunities to identify individuals at increased risk of developing the disease.
Researchers at the University of Cambridge analyzed blood samples collected annually from 47 women who subsequently developed AML and 46 age-matched controls who remained free of blood cancer. Samples were available from as early as 15 years before diagnosis.
Using a highly sensitive sequencing approach called TETRIS-seq, the team tracked mutations associated with AML and measured how populations of blood cells carrying these mutations changed over time.
The findings suggest that AML develops through a series of genetic changes, often beginning early in life. In approximately two-thirds of participants who developed AML, the first cancer-associated mutation was estimated to have appeared before age 20.
Initially, affected blood cell populations grew slowly, often taking years to double in size. However, as additional mutations accumulated, their growth accelerated substantially. Cells carrying several mutations could eventually dominate blood production, sometimes decades before leukemia became clinically apparent.
This pattern distinguished future AML cases from healthy controls. Although age-related mutations were common in both groups, the researchers observed much more extensive expansion and competition between mutated cell populations among those who subsequently developed leukemia.
Importantly, analysis of UK Biobank data supported the potential diagnostic significance of these findings. Individuals whose blood showed evidence of extensive expansion of a mutated cell population had substantially increased odds of developing myeloid leukemia.
The results suggest that molecular risk assessment could be improved by examining not only which mutations are present, but also how extensively affected cells have expanded. Current sequencing analysis pipelines may overlook some high-frequency acquired mutations because they resemble inherited genetic variants.
However, the findings do not establish a screening test. The study involved a relatively small cohort of older women, and approximately one-fifth of AML cases showed little detectable warning before diagnosis.
Further validation will be needed to determine whether monitoring these genetic changes can reliably identify high-risk individuals and guide preventive intervention.
